PhRMA commitment to boosting trial diversity emphasizes community trust and outreach

The first problem area PhRMA seeks to address through its trial diversity guidelines, released last week, is the lack of trust among underserved communities when it comes to clinical studies. 

The guidelines, which are voluntary and will take effect in April, coincided with the launch of a $100 million initiative by Bristol Myers Squibb Foundation and National Medical Fellowships to improve diversity in clinical trial enrollment via a career development program that will train investigators in community engagement. ...